World Allergy Organization Journal
A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis
By Laura Pini, MD, Diego Bagnasco, MD, Bianca Beghè, MD and 7 others.
Abstract
Background
Clinical remission is increasingly recognized as a primary treatment goal in severe asthma, particularly severe eosinophilic asthma (SEA), where comorbidities such as chronic rhinosinusitis with nasal polyps (CRSwNP) contribute to persistent inflammation and treatment burden. Benralizumab, an anti–IL-5Rα monoclonal antibody, has shown efficacy in achieving sustained control in SEA, but long-term real-world data beyond 36 months remain limited.